Keywords: preladenant, reduces, off-time, ph, ii, pd, trial
Preladenant reduces off-time in Ph II PD trial
Article | 08 December 2008
US drug major Schering-Plough's preladenant met the primary endpoint in a Phase II dose-finding trial in patients suffering from moderate-to-severe ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
